Compensation — Executive Directors' Remuneration (FY2025)
Fiscal year 2025
- AstraZeneca is an FPI that files Form 20-F. Compensation data is incorporated by reference from Exhibit 15.1 (Annual Report and Form 20-F Information 2025), specifically the Directors' Remuneration Report on pages 90–113.
- The filing reports in GBP (£'000). USD equivalents below use the approximate 2025 average GBP/USD rate of 1.2741 (model inferred; actual AstraZeneca group financials translate at average rates per IFRS accounting policy).
- Pascal Soriot (CEO) FY2025 single total figure of remuneration: £17,696,000 (~$22,546,000 USD). Components: Base pay £1,545k, Taxable benefits £143k, Pension £170k, Annual bonus £4,259k (92% of maximum / 184% of target; split 50% cash, 50% deferred shares), Long-term incentives £11,579k (2023 PSP vesting at 97% of maximum).
- Aradhana Sarin (CFO) FY2025 single total figure of remuneration: £7,846,000 (~$9,997,000 USD). Components: Base pay £990k, Taxable benefits £10k, Pension £109k, Annual bonus £1,603k (81% of maximum / 162% of target; split 50% cash, 50% deferred shares), Long-term incentives £5,134k (2023 PSP vesting at 97% of maximum).
- FY2025 annual bonus determined at 184% of target for CEO and 162% of target for CFO, based on 2025 Group scorecard formulaic outcome of 147% of target. Scorecard weighted 30% Science & Innovation (achieved 51% of target), 70% Financial (achieved 96% of target).
- 2023 PSP awards granted 4 March 2023 vested at 97% of maximum. Performance period 1 January 2023 to 31 December 2025. PSP performance measures: Science & Innovation 30% (achieved 30%), Growth & Therapy Area Leadership 20% (achieved 20%), Cash flow 20% (achieved 20%), Relative TSR 20% (AZN ranked 6th; achieved 17%), Ambition Zero Carbon 10% (achieved 10%). Total 97%.
- 2025 PSP awards granted 4 March 2025 at 850% of base pay for CEO (109,781 shares, face value £13,133k) and 550% of base pay for CFO (45,494 shares, face value £5,442k). Grant price 11,963 pence. 3-year performance period ending 31 December 2027 with 2-year holding period.
- DBP awards: CEO deferred £2,129.5k (14,623 shares granted 4 March 2025, price 11,963p); CFO deferred £801.5k (6,243 shares granted 4 March 2025, price 11,963p). These represent 50% of 2024 annual bonus deferred.
- Malus and clawback: provisions apply for two years from payment, grant, or vesting. No malus or clawback was exercised in 2025.
- 2025 PSP long-term incentives: CEO 2023 PSP value £11,579k (85,808 shares, 97% vesting; face value at grant £9,006k, share price appreciation £1,982k, dividend equivalents £591k). CFO 2023 PSP value £5,134k (38,046 shares, 97% vesting; face value at grant £3,993k, share price appreciation £879k, dividend equivalents £262k). Average share price over 3-month period ended 31 December 2025: 13,202 pence.
Key figures
- soriot_base_pay_gbp
- $1,968,484reported in £'000, converted to units
- soriot_annual_bonus_gbp
- $5,426,392reported in £'000, converted to units
- soriot_lti_gbp
- $14,752,804reported in £'000, converted to units
- soriot_total_gbp
- $22,546,474reported in £'000, converted to units
- sarin_base_pay_gbp
- $1,261,359reported in £'000, converted to units
- sarin_annual_bonus_gbp
- $2,042,382reported in £'000, converted to units
- sarin_lti_gbp
- $6,541,229reported in £'000, converted to units
- sarin_total_gbp
- $9,996,589reported in £'000, converted to units